Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1CNS 1Breast 1

Conditions

Carcinoma, Renal Cell 9Wilms Tumor 5Pancreatic Neoplasms 5Kidney Neoplasms 5Colorectal Neoplasms 5Breast Neoplasms 5Urinary Bladder Neoplasms 4Ovarian Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Prostatic Neoplasms 3Neuroblastoma 3Neoplasms 3Melanoma 3Lung Neoplasms 3Colonic Neoplasms 3Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma 2Rectal Neoplasms 2Neoplasm Metastasis 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Bone Neoplasms 2Uterine Cervical Neoplasms 1Urethral Neoplasms 1Stage I Mixed Cell Type Kidney Wilms Tumor 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1

Interventions

olaparib 2Carboplatin 2pembrolizumab 1liposomal doxorubicin 1Taxes 1Paclitaxel 1Lomustine 1Irinotecan 1Gemcitabine 1Doxorubicin 1CYH33 1Albumin-Bound Paclitaxel 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hereditary Sensory and Autonomic Neuropathies × Irinotecan × Genitourinary × Clear all
NCT03678883 2026-04-03

9-ING-41 in Patients With Advanced Cancers

Actuate Therapeutics Inc.

Phase 2 Active not recruiting
350 enrolled
BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡